{
  "CDMO Response 3.pdf": "CDMO Response 3 \u2013 Thermo Fisher Scientific (Viral Vector Services, Lexington, MA)  \nSection 1 \u2013 Company Overview  \nThermo Fisher offers integrated Gene Therapy CDMO  services combining viral vector \nmanufacturing, fill/finish, and analytical testing.  \nThe Lexington, MA  site provides commercial AAV manufacturing under FDA/EMA \nlicensure, while the Alachua, FL  site supports early -phase work and redundancy.  \nSection 2 \u2013 Technical Approach  \n\u2022 Tech Transfer:  Thermo Fisher\u2019s \u201cFastPath\u201d platform enables streamlined transfer in \n4\u20136 months.  \n\u2022 Manufacturing System:  Closed single -use bioreactor trains (1,000 \u20132,000 L).  \n\u2022 Yield Maximization:  Proprietary AAV recovery process provides up to 30% higher \nvg/mL recovery compared to traditional column chromatography.  \nSection 3 \u2013 Project Plan  \nStep  Target Completion  \nProcess & Method Transfer  Q2 2026  \nEngineering Run  Q3 2026  \nPPQ Batches  Q4 2026\u2013Q1 2027  \nLaunch Readiness  Q2 2027  \nDedicated Client Success Team  assigned with integrated planning and logistics support.  \nSection 4 \u2013 Regulatory & Quality  \n\u2022 FDA-inspected in 2024 (no Form 483).  \n\u2022 EMA, MHRA, and PMDA recognized site.  \n\u2022 Track record supporting over 20 approved biologics and 5 gene therapy launches.  \n\u2022 Supports serialization, global distribution, and import/export compliance.  \nSection 5 \u2013 Cost Proposal (Indicative)  Activity  Cost per Batch  Notes  \nDS Manufacturing  $490,000  1,000 L single -use  \nDP Fill/Finish  $80,000  Fully integrated  \nQC & Stability  $45,000  Includes release & 12 -month stability  \nTech Transfer Fee  $300,000  Fixed  \nStorage  $1.40/vial/month  Includes monitoring  \nAssumptions:  Analytical reference standards provided by client; DP label & pack \nexcluded.",
  "CDMO Response 1.pdf": "CDMO Response 1 \u2013 Lonza AG (Large Global Gene Therapy CDMO)  \nSection 1 \u2013 Company Overview  \nLonza is a leading global CDMO with >125 years of manufacturing heritage and over 25 \nyears of gene therapy expertise. Our facilities in Portsmouth, NH  and Visp, Switzerland  \nare fully licensed for AAV commercial production under FDA and EMA oversight.  \nWe currently support >10 commercial viral vector programs and offer full DS \u2013DP \nintegration.  \nSection 2 \u2013 Technical Approach  \n\u2022 Tech Transfer:  We follow a structured 4 -phase process (Assessment \u2192 Transfer \u2192 \nVerification \u2192 Validation) with full comparability data packages.  \n\u2022 Scale & Process:  Up to 2,000 L iCELLis and stirred -tank platforms; tech transfer \ncompleted within 6 months.  \n\u2022 Optimization:  Employ continuous perfusion and closed processing for yield \nimprovement (~20 \u201325%).  \nSection 3 \u2013 Project Plan  \nMilestone  Description  Timing  \nKickoff & Data Review  Receive full process documentation  Q1 2026  \nEngineering Batch  Confirm process equivalence  Q2 2026  \nValidation Batches  Three PPQ batches under cGMP  Q4 2026  \nCommercial Supply  Launch and annual supply  Q2 2027 onward  \nLonza assigns a dedicated Program Manager  and CMC Tech Lead . Business continuity \nincludes dual -site production (US + EU) and in -house QC analytics.  \nSection 4 \u2013 Regulatory & Quality  \n\u2022 Inspected by FDA (2023) and EMA (2024) with no major observations.  \n\u2022 ISO 9001:2015 certified; integrated QMS via Veeva Vault.  \n\u2022 Digital batch records and AI -based deviation trending implemented in 2024.  \nSection 5 \u2013 Cost Proposal (Indicative)  Activity  Cost per Batch  Notes  \nDS Manufacturing (1,000 L)  $510,000  Includes raw materials  \nDP Fill/Finish  $60,000  2 mL/5 mL vials  \nQC & Release  $30,000  Sterility, potency, AAV titer  \nTech Transfer Fee  $275,000  One-time  \nStorage  $1.75/vial/month  -80\u00b0C storage  \nAssumptions:  Client provides reference material; long -term stability managed externally."
}